BioTrinity Attendence Continues to Rise

OBN, a membership organisation supporting the UK’s innovative life sciences companies, announced that its annual BioTrinity event again proved to be a leading European investment and biopartnering conference. 

John Harris, CEO of OBN, said: “For its 10^th edition BioTrinity has been a fabulous success. The large number of delegates from across Europe, with a record number of investors and extremely high calibre panellists, confirms BioTrinity’s position as a key meeting in the European life sciences calendar. We would like to thank all our sponsors and speakers and already look forward to the 11^th edition in 2017.”

The success of BioTrinity 2016 was demonstrated by the post show statistics reflecting attendance of 1020 delegates from over 637 companies from more than 30 countries across Europe, Asia and North America: Participation of more than 181 investors specialising in funding emerging biotechnology and life sciences companies as well as more than 60 pharmaceutical company delegates: 91 company pitches for partners and investment among 204 speakers throughout the two-day conference.

This year also saw 2518 one-to-one partnering meetings scheduled and a new Perfect Pitch session with 9 life science companies pitching to a floor of experienced investors. The winner was Elasmogen Ltd for its soloMERä technology that enables site specific delivery of biologics to challenging environments such as the eye and gut.

Scott C. Brun, Vice President, Corporate Strategy Office at AbbVie Ventures, commented: "AbbVie is proud to be a sponsor of the BioTrinity 2016 investment and biopartnering conference. Our team found the meeting to be an effective way to network with proven investors and cutting edge entrepreneurs in order to strengthen relationships and jointly identify emerging science with the potential to transform care in our core areas of oncology, immunologic and neurodegenerative diseases.”